CL2022002598A1 - Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos - Google Patents
Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usosInfo
- Publication number
- CL2022002598A1 CL2022002598A1 CL2022002598A CL2022002598A CL2022002598A1 CL 2022002598 A1 CL2022002598 A1 CL 2022002598A1 CL 2022002598 A CL2022002598 A CL 2022002598A CL 2022002598 A CL2022002598 A CL 2022002598A CL 2022002598 A1 CL2022002598 A1 CL 2022002598A1
- Authority
- CL
- Chile
- Prior art keywords
- receptor agonist
- agonist peptide
- gip receptor
- peptide compounds
- dosage
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 239000000018 receptor agonist Substances 0.000 title abstract 4
- 229940044601 receptor agonist Drugs 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 abstract 4
- 206010047700 Vomiting Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062994716P | 2020-03-25 | 2020-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022002598A1 true CL2022002598A1 (es) | 2023-06-02 |
Family
ID=76502784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022002598A CL2022002598A1 (es) | 2020-03-25 | 2022-09-23 | Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220227830A1 (enExample) |
| EP (1) | EP4126921A2 (enExample) |
| JP (1) | JP2023519446A (enExample) |
| KR (1) | KR20230005184A (enExample) |
| CN (1) | CN115335395A (enExample) |
| AR (1) | AR121650A1 (enExample) |
| AU (1) | AU2021241257A1 (enExample) |
| BR (1) | BR112022019114A2 (enExample) |
| CA (1) | CA3173129A1 (enExample) |
| CL (1) | CL2022002598A1 (enExample) |
| CO (1) | CO2022014959A2 (enExample) |
| EC (1) | ECSP22074680A (enExample) |
| IL (1) | IL296592A (enExample) |
| MX (1) | MX2022011816A (enExample) |
| PE (1) | PE20230107A1 (enExample) |
| PH (1) | PH12022552562A1 (enExample) |
| TW (1) | TW202202516A (enExample) |
| WO (1) | WO2021193984A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220016215A1 (en) * | 2018-09-24 | 2022-01-20 | Takeda Phaarmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| IL296219A (en) * | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | Qw dosing of gip receptor agonist peptide compounds and uses thereof |
| CN118754965A (zh) | 2020-05-29 | 2024-10-11 | 北京拓界生物医药科技有限公司 | Glp-1和gip受体双重激动剂化合物及其应用 |
| WO2023139106A2 (en) * | 2022-01-18 | 2023-07-27 | Novo Nordisk A/S | Long-acting gipr antagonists |
| WO2025154020A1 (en) * | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
| WO2025154021A1 (en) * | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| EP1302462A4 (en) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF |
| BR0315815A (pt) | 2002-11-01 | 2005-09-13 | Takeda Pharmaceutical | Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto |
| AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND ITS USE |
| WO2005058823A1 (ja) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | ウレア誘導体、その製造法及び用途 |
| US7456218B2 (en) | 2003-12-25 | 2008-11-25 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| WO2005087710A1 (ja) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | アミノフェニルプロパン酸誘導体 |
| JP4859665B2 (ja) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| CA2597649A1 (en) * | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
| US20090054435A1 (en) | 2005-07-29 | 2009-02-26 | Hiroshi Imoto | Phenoxyalkanoic Acid Compound |
| EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| JP4094660B1 (ja) | 2005-08-10 | 2008-06-04 | 武田薬品工業株式会社 | 糖尿病治療剤 |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| AU2007265966B2 (en) | 2006-06-27 | 2012-05-17 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
| US8497240B2 (en) * | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| CN101573357B (zh) | 2006-10-19 | 2013-01-23 | 武田药品工业株式会社 | 吲哚化合物 |
| WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| AU2008215490A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of PPAR-gamma |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| EP2157859A4 (en) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE |
| CA2872314C (en) * | 2012-05-03 | 2021-08-31 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| SI2864350T1 (en) * | 2012-06-21 | 2018-08-31 | Indiana University Research And Technology Corporation | GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR |
| DK3004155T3 (da) * | 2013-05-28 | 2022-01-03 | Takeda Pharmaceuticals Co | Peptidforbindelse |
| JOP20190211A1 (ar) * | 2017-03-31 | 2019-09-15 | Takeda Pharmaceuticals Co | ببتيد منشط لمستقبل gip |
| TWI912614B (zh) * | 2017-12-21 | 2026-01-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| US20220016215A1 (en) * | 2018-09-24 | 2022-01-20 | Takeda Phaarmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
-
2021
- 2021-03-25 IL IL296592A patent/IL296592A/en unknown
- 2021-03-25 JP JP2023502029A patent/JP2023519446A/ja active Pending
- 2021-03-25 KR KR1020227037256A patent/KR20230005184A/ko not_active Ceased
- 2021-03-25 MX MX2022011816A patent/MX2022011816A/es unknown
- 2021-03-25 BR BR112022019114A patent/BR112022019114A2/pt unknown
- 2021-03-25 AR ARP210100730A patent/AR121650A1/es unknown
- 2021-03-25 WO PCT/JP2021/014423 patent/WO2021193984A2/en not_active Ceased
- 2021-03-25 CN CN202180023814.5A patent/CN115335395A/zh active Pending
- 2021-03-25 EP EP21733232.9A patent/EP4126921A2/en active Pending
- 2021-03-25 TW TW110110874A patent/TW202202516A/zh unknown
- 2021-03-25 AU AU2021241257A patent/AU2021241257A1/en active Pending
- 2021-03-25 PH PH1/2022/552562A patent/PH12022552562A1/en unknown
- 2021-03-25 PE PE2022002094A patent/PE20230107A1/es unknown
- 2021-03-25 CA CA3173129A patent/CA3173129A1/en active Pending
- 2021-12-17 US US17/554,539 patent/US20220227830A1/en not_active Abandoned
-
2022
- 2022-09-23 CL CL2022002598A patent/CL2022002598A1/es unknown
- 2022-09-23 EC ECSENADI202274680A patent/ECSP22074680A/es unknown
- 2022-10-20 CO CONC2022/0014959A patent/CO2022014959A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20230107A1 (es) | 2023-01-25 |
| MX2022011816A (es) | 2022-10-10 |
| US20220227830A1 (en) | 2022-07-21 |
| CO2022014959A2 (es) | 2022-11-08 |
| EP4126921A2 (en) | 2023-02-08 |
| WO2021193984A3 (en) | 2021-12-16 |
| AU2021241257A1 (en) | 2022-10-13 |
| PH12022552562A1 (en) | 2022-12-19 |
| AR121650A1 (es) | 2022-06-22 |
| BR112022019114A2 (pt) | 2023-02-14 |
| KR20230005184A (ko) | 2023-01-09 |
| TW202202516A (zh) | 2022-01-16 |
| JP2023519446A (ja) | 2023-05-10 |
| CN115335395A (zh) | 2022-11-11 |
| ECSP22074680A (es) | 2022-10-31 |
| WO2021193984A2 (en) | 2021-09-30 |
| CA3173129A1 (en) | 2021-09-30 |
| IL296592A (en) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022014959A2 (es) | Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos | |
| CL2022002597A1 (es) | Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos | |
| CO2019012271A2 (es) | Péptido activador de receptor de gip | |
| CL2021002772A1 (es) | Moduladores de la vía de respuesta integrada al estrés | |
| UY40873A (es) | Compuestos cíclicos puenteados y composiciones farmacéuticas y usos de los mismos para modular la respuesta integrada al estrés y para tratar enfermedades relacionadas | |
| MX2020006438A (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1. | |
| MX2019004616A (es) | Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina. | |
| SV2018005778A (es) | Derivados aromaticos de sulfonamida | |
| CL2017000156A1 (es) | Procedimientos para el tratamiento de paramixovirus. | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| CO2022001814A2 (es) | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos | |
| MX2021005945A (es) | Ureas ciclicas. | |
| MX2020011405A (es) | Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos. | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| CO2022009510A2 (es) | Compuestos activos frente a receptores nucleares | |
| CL2021000329A1 (es) | Compuestos útiles en terapia del vih | |
| CL2019001991A1 (es) | Moduladores del receptor de estrógeno. | |
| MX2021015543A (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo. | |
| AR114418A1 (es) | Compuesto cíclico de metilactama y su utilización farmacéutica | |
| MX390507B (es) | Compuestos de amida y su uso. | |
| CO2020002967A2 (es) | Desinfectante novedoso para criaderos | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| AR102248A1 (es) | Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes | |
| MX2020003832A (es) | Compuestos heteroarilos como moduladores alostericos positivos del receptor muscarinico m1. | |
| MX2022012259A (es) | Compuestos activos frente a receptores nucleares. |